Design Therapeutics, Inc. (DSGN)
|Net Income (ttm)||n/a|
|Trading Day||June 17|
|Day's Range||25.20 - 28.11|
|52-Week Range||18.55 - 50.50|
CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João S...
CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appoin...
Successful $276 Million IPO Completed to Advance GeneTAC TM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development
Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchas...
CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecule...
CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of ser...
Design Therapeutics, a preclinical biotech developing gene targeted chimeras for nucleotide expansion diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Design Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Design Therapeutics is a preclinical-stage biopharmaceutical company pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs), that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases, of which there are more than 40 debilitating degenerative diseases. Individuals with nucleotide repeat expansion diseases are born with abnormally expanded stretches of specific nucleotide sequences, often with hundreds to thousands of excess repeats present... [Read more...]
|IPO Date |
Mar 26, 2021
Jou00e3o Siffert, M.D.
|Stock Exchange |
|Ticker Symbol |
In 2020, DSGN's revenue was $226,000, a decrease of -72.90% compared to the previous year's $834,000. Losses were -$8.28 million, 304.5% more than in 2019.
The average 12-month stock price forecast for DSGN is 35.33, which is an increase of 39.75% from the latest price.